ArticleFrontiers in endocrinology2026
Stigmasterol ameliorates obesity-associated insulin resistance by activating the PPARγ pathway and alleviating oxidative stress.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the effects of stigmasterol on obesity-related insulin resistance and to explore the underlying molecular mechanisms. Methods: Network pharmacology was used to screen the active components and key targets of Angelica sinensis that act on obesity and insulin resistance, and molecular docking was performed to assess the binding potential between stigmasterol and PPARγ. In cell experiments, an insulin-resistant 3T3-L1 adipocyte model was treated with different concentrations of stigmasterol and rosiglitazone. Lipid accumulation, oxidative stress indicators, and protein expression of the PPARγ pathway were measured. In animal experiments, high-fat diet-induced obese mice were administered stigmasterol and rosiglitazone, and serum metabolic parameters, histopathological changes, and hepatic oxidative stress and PPARγ pathway protein expression were measured. Results: Network pharmacology identified 90 overlapping targets, with PPARγ occupying a central position in the core network. Molecular docking indicated that stigmasterol showed good binding affinity for PPARγ. In insulin-resistant 3T3-L1 adipocytes, stigmasterol reduced intracellular TG and TC contents and lipid droplet accumulation, decreased ROS and MDA levels, increased the activities of CAT, GPx, and SOD, and upregulated the protein expression of PPARγ, the p-Akt/Akt ratio, and GLUT4 (p < 0.05). In obese mice, stigmasterol decreased the serum levels of fasting insulin, fasting blood glucose, HOMA-IR, TG, and TC, increased HOMA-ISI, reduced adipocyte size, alleviated hepatic steatosis, and lowered serum ALT and AST levels. Meanwhile, stigmasterol reduced hepatic ROS and MDA levels, restored antioxidant enzyme activities, and upregulated the protein expression of PPARγ, p-Akt/Akt, and GLUT4 in the liver (p < 0.05). Conclusion: Stigmasterol improved obesity-related glycolipid metabolic disorder and insulin resistance both
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.